Dry and Wet Age-Related Macular Degeneration – Current Treatment – Treatment Algorithms: Claims Data Analysis – Wet Age-Related Macular Degeneration (US)
The U.S. market for wet age-related macular degeneration (wet AMD) is in transition as newer therapies, including biosimilars, increasingly enter the treatment algorithm. While intravitreal options such as Avastin (used off-label) and Regeneron’s Eylea remain widely prescribed, this report examines patient switching patterns toward Regeneron’s Eylea HD, Roche’s Vabysmo, and a biosimilar version of Eylea (Amgen’s Pavblu). It also evaluates whether the off-label use of compounded Avastin as a first-line therapy in newly diagnosed patients is changing, signaling shifts in prescribing behavior and competitive dynamics. It examines patient share trends, therapy sequencing, and persistency trends. By analyzing treatment initiation, progression, and patient flow using claims data, this report provides stakeholders with a comprehensive view of evolving patterns that may influence market positioning and strategic planning of their pipeline assets.
Questions answered
- What patient shares do key brands garner by line of therapy in newly diagnosed wet AMD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed wet AMD patients?
- How has Amgen’s Pavblu been integrated into the treatment algorithm, and what is its source of business?
- What percentage of wet AMD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of wet AMD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key drugs: Avastin, Eylea, Lucentis, Beovu, Vabysmo, Eylea HD, Susvimo, Pavblu, biosimilars of Avastin, biosimilars of Lucentis
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
